Liminatus Pharma moves Nasdaq listing to Capital Market tier

• Liminatus Pharma moved its Nasdaq listing to the Nasdaq Capital Market, effective Aug. 4, 2026.
• Shares continue trading on Nasdaq under the LIMN ticker following the transfer.
• Nasdaq granted an extension to regain the minimum bid price requirement, setting a Sept. 3, 2026 deadline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130715PRIMZONEFULLFEED9809373) on August 13, 2026, and is solely responsible for the information contained therein.